CRISPR Therapeutics Faces Its Biggest Test Yet: Common Disease
Phase 1b data for CTX310 hit Monday morning at AHA, with the big question: can one IV infusion scale into cardiology?
Iran Peace Talks Are Moving Oil More Than the War Did
Brent’s post-election slide is about diplomacy odds, not supply.
Tesla Retired a Product. Now the Math Has to Work on Cybercab.
Ending the Cybertruck costs Tesla little. What comes next costs investors everything in assumptions.
The Stoxx 600 Fell With Everything Else. So What Is Your Portfolio Protected By?
Europe’s low-AI buffer lasted two days before every sector turned red, raising a harder question about where genuine diversification lives.
Japan’s Stock Market Crashed 6%. The Yen Barely Moved.
When the currency refuses to follow the selloff, that is a signal worth reading carefully.
Commerzbank Posted a 45% Profit Jump. Here’s What It Means
European bank dividends and buybacks are delivering returns many U.S. investors have missed.
Datadog’s Growth Is Fine. Its Biggest Customer Is the Problem.
A single unnamed AI customer, modeled at its minimum for Q4, turned a 35% growth quarter into an 18% stock drop.
The Treasury Refunding Hits a Bond Market Already Moving
Auction sizes and long-end buybacks are on the table this morning, and the 10-year yield already gave back ground overnight.
Novo Nordisk Just Proved the Price War Story Was Wrong
A beat on every line and a third guidance raise in 2026 show the Wegovy pill is filling the gap faster than investors feared.
Vulcan’s Real Bet Is on Money Not Spent Yet
With roughly half of IIJA outlays still pending, Vulcan is pricing 2027 on backlog